Leadership

Our Vision and Mission

iCAD is a global leader in medical technology providing innovative cancer detection and therapy solutions. Through passionate ingenuity, iCAD delivers transformative innovations to precisely and effectively predict, detect and treat cancer earlier, empowering clinicians to provide quality, cost-effective patient care.

 

Our transformative technologies are proven to improve patient outcomes with increased accuracy and efficiency. Our commitment to advancing access to our cutting-edge solutions is driven by the valuable benefits they offer to physicians, facilities, and patients worldwide.

 “I believe that iCAD’s unique AI technology has the potential to transform both cancer detection and the assessment of at-risk patients. We are fervently focused on unlocking the significant inherent value that exists in iCAD’s core technology, market presence and huge repository of CAD interpreted images.”

— Michael Klein - Executive Chairman and CEO

Our Leadership

Michael Klein
Executive Chairman and CEO

| LinkedIn

Stacey Stevens
President

| LinkedIn

R. Scott Areglado
Chief Financial Officer

| LinkedIn

Jonathan Go
Chief Technology Officer

| LinkedIn

Our Board of Directors

Michael Klein
Chairman and CEO

| LinkedIn

Dr. Rakesh Patel
Chief Executive Officer,
Precision Cancer Care Specialists Medical Group

| LinkedIn

Andrew H. Sassine
Chief Financial Officer, Arcturus Therapeutics

| LinkedIn

Susan Wood, Ph.D.
Chief Executive Officer, VIDA Diagnostics

| LinkedIn

A medical technology leader providing innovative cancer detection and therapy solutions worldwide

© 2019, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo,, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

 

“I believe that iCAD’s unique AI technology has the potential to transform both cancer detection and the assessment of at-risk patients. We are fervently focused on unlocking the significant inherent value that exists in iCAD’s core technology, market presence and huge repository of CAD interpreted images.”

— Michael Klein - Executive Chairman
and CEO